CD274 and head and neck squamous cell carcinoma: Recently, two PET agents, 89Zr-DFO-durvalumab and 18F-BMS-986192, have been applied in clinical trials to assess PD-L1 expression in HNSCC patients (ClinicalTrials.gov identifiers NCT 03829007 and NCT 03843515).